Hip Arthroscopy Pain Control Randomized Control Trial (RCT)
CompletedPhase 4NCT02947178
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Femoroacetabular impingement is a pathologic process within the hip joint that results from a mechanical discord between the femoral head and neck and the acetabulum that results in chronic hip pain, hip labral tears and early progression of osteoarthritis of the hip.1, 2 Historically an open surgical hip dislocation was performed to treat patients with this condition, however with recent advances in arthroscopy, patients more commonly now undergo arthroscopic hip surgery. From a pain management standpoint, previous attempts to provide peri-operative analgesia included intraarticular or portal analgesic injections. More recently, regional anesthesia techniques are being employed to provide more reliable and longer lasting post-operative pain control.3, 4 Currently, there are several local anesthetics available for regional anesthesia. However, they only provide an average of 12-18 hours of post-operative pain control following a single injection.5 Bupivacaine is a local anesthetic that has been used for many years by multiple routes to control post-operative pain. A new formulation of the medication prolongs the release of the active ingredient after a single injection and has been shown to result in up to 72 hours of post-operative analgesia.6, 7 To the investigator's knowledge, there has not been any studies in the literature comparing a historical control local anesthetic to this new formulation of liposomal bupivacaine via a fascial iliaca regional soft tissue infiltration blockade to provide post operative pain control following hip arthroscopy.
Study details
- Official title
- Liposomal Bupivacaine Versus Bupivacaine With Fascia Iliaca Blockade for Perioperative Pain Management During Hip Arthroscopy: A Double-Blinded Prospective Randomized Control Trial
- Conditions
- Hip Pain Chronic
- Anesthesia
- Bupivacaine
- Interventions
- Procedure: Fascial iliac regional soft tissue infiltration blockade
- Behavioral: Pain Score Survey
- Behavioral: Pill Count
- Drug: Bupivacaine
- Drug: Liposomal Bupivacaine
- Sponsor
- Walter Reed National Military Medical Center
- Start date
- 2016-03-01
- Primary completion
- 2017-03-01
- Sex
- All
- Age range
- from 18 Years to 50 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Patient is scheduled to undergo hip arthroscopy 2. Patient is between 18-50 years of age 3. DEERS eligibility Exclusion Criteria: 1. Patients who are on a medication pre-operatively that would prohibit them from receiving one of the study medications 2. Patient is unable to speak/read the English language (Currently, the DVPRS has only been scientifically validated in the English language and translating to languages other than English would compromise the validity of the pain scale) 3. Patient has a history of previous hip arthroscopy surgery 4. The patient is pregnant - ruled out with routine urine pregnancy test the morning of surgery in the anesthesia pre-operative unit. 5. The patient carries a pre-existing diagnosis of a pain disorder. (Example: Fibromyalgia) 6. The patient has a previous history of narcotic pain medication abuse. 7. The patient has an allergy to one of the study medications
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02947178